cilastatin--imipenem-drug-combination and clinafloxacin

A deep-seated Pseudomonas aeruginosa mouse kidney abscess model was used to compare the therapeutic efficacy of clinafloxacin, a fluoroquinolone in clinical trials, with that of clinically relevant standard drugs. Following 50 mg/kg oral doses, twice daily for five consecutive days, clinafloxacin produced a 4 log decrease in mean bacterial count, the greatest decrease of all drugs tested. The same dosage regimen resulted in complete bacterial eradication in 88% of the kidneys. No other compound produced total bacterial clearance in 50% of the kidneys at the highest dose tested.

Topics: Abscess; Animals; Anti-Infective Agents; Area Under Curve; Ceftazidime; Cilastatin; Cilastatin, Imipenem Drug Combination; Ciprofloxacin; Colony Count, Microbial; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Female; Fluoroquinolones; Half-Life; Imipenem; Kidney; Kidney Diseases; Mice; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones; Treatment Outcome